- 入驻时间: 2015-11-06
- 联系人:顾磊
- 电话:021-60514606
-
联系时,请说明易展网看到的
- Email:shybio@126.com
脂蛋白关联磷脂酶A2(LpPLA2)重组蛋白
- 物种Homo sapiens (Human,人)相同的名称,不同的物种。
- 片段与标签Phe22~Asn441 (Accession # Q13093) with N-terminal His Tag宿主E.coli
- 内**水平<1.0EU/µg(LAL法测定)
- 亚细胞定位Secreted, extracellular space
- 预测分子量50.0kDa
- 实际分子量-(差异分析请参阅说明书)
- 缓冲液成份磷酸盐缓冲液(pH7.4,含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.)
- 性状冻干粉
- 纯度> 80%
- 等电点7.1
-
脂蛋白关联磷脂酶A2(LpPLA2)重组蛋白应用SDS-PAGE; WB; ELISA; IP
用法
PBS或其它。
储存
避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
脂蛋白关联磷脂酶A2(LpPLA2)重组蛋白
Phospholipase A2, Lipoprotein Associated (LpPLA2)
Organism Species: Homo sapiens (Human)
Instruction manual
FOR IN VITRO USE AND RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES
9th Edition (Revised in Jul, 2013)
脂蛋白关联磷脂酶A2(LpPLA2)重组蛋白[ PROPERTIES ]
Residues: Phe22~Asn441 (Accession # Q13093),
with N-terminal His-Tag.
Host: E. coli
Subcellular Location: Secreted, extracellular
space.
Purity: >95%
Endotoxin Level: <1.0EU per 1μg
(determined by the LAL method).
Formulation: Supplied as lyophilized form in PBS,
pH7.4, containing 5% sucrose, 0.01% sarcosyl.
Predicted isoelectric point: 7.1
Predicted Molecular Mass: 50.0kDa
[ USAGE ]
Reconstitute in sterile PBS, pH7.2-pH7.4.
[ STORAGE AND STABILITY ]
Storage: Avoid repeated freeze/thaw cycles.
Store at 2-8oC for one month.
Aliquot and store at -80oC for 12 months.
Stability Test: The thermal stability is described by the loss rate of the target
protein. The loss rate was determined by accelerated thermal degradation test,
that is, incubate the protein at 37oC for 48h, and no obvious degradation and
precipitation were observed. (Referring from China Biological Products Standard,
which was calculated by the Arrhenius equation.) The loss of this protein is less
than 5% within the expiration date under appropriate storage condition.
脂蛋白关联磷脂酶A2(LpPLA2)重组蛋白[ SEQUENCES ]
The target protein is fused with N-terminal His-Tag, its sequence is listed below.
MGHHHHHHSGSEFELRRQ- FDWQYINPV AHMKSSAWVN KIQVLMAAAS FGQTKIPRGN
GPYSVGCTDL MFDHTNKGTF LRLYYPSQDN DRLDTLWIPN KEYFWGLSKF LGTHWLMGNI
LRLLFGSMTT PANWNSPLRP GEKYPLVVFS HGLGAFRTLY SAIGIDLASH GFIVAAVEHR
DRSASATYYF KDQSAAEIGD KSWLYLRTLK QEEETHIRNE QVRQRAKECS QALSLILDID
HGKPVKNALD LKFDMEQLKD SIDREKIAVI GHSFGGATVI QTLSEDQRFR CGIALDAWMF
PLGDEVYSRI PQPLFFINSE YFQYPANIIK MKKCYSPDKE RKMITIRGSV HQNFADFTFA
TGKIIGHMLK LKGDIDSNVA IDLSNKASLA FLQKHLGLHK DFDQWDCLIE GDDENLIPGT
NINTTNQHIM LQNSSGIEKY N
[ REFERENCES ]
1. Samanta U., et al. (2009) Biochem. Pharmacol. 78:420-429. 2. Samanta U., Bahnson B.J. (2008) J. Biol. Chem. 283:31617-31624. 3. The MGC Project Team. (2004) Genome Res. 14:2121-2127. 4. Lu Y., et al. (2008) J. Lipid Res. 49:2582-2589.